HC Wainwright Has Negative Outlook of IOVA Q3 Earnings

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Analysts at HC Wainwright decreased their Q3 2025 EPS estimates for Iovance Biotherapeutics in a research note issued on Wednesday, October 29th. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will post earnings per share of ($0.30) for the quarter, down from their prior forecast of ($0.26). HC Wainwright has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($1.24) per share. HC Wainwright also issued estimates for Iovance Biotherapeutics’ Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.29) EPS, FY2026 earnings at ($1.07) EPS and FY2027 earnings at ($0.79) EPS.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.04). The business had revenue of $59.95 million for the quarter, compared to the consensus estimate of $67.14 million. Iovance Biotherapeutics had a negative net margin of 161.44% and a negative return on equity of 52.87%. Iovance Biotherapeutics has set its FY 2025 guidance at EPS.

Several other research analysts have also issued reports on the stock. Zacks Research upgraded shares of Iovance Biotherapeutics to a “hold” rating in a research report on Tuesday, August 12th. The Goldman Sachs Group lowered shares of Iovance Biotherapeutics from a “neutral” rating to a “sell” rating in a research report on Tuesday, July 15th. Chardan Capital decreased their price target on shares of Iovance Biotherapeutics from $25.00 to $20.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Iovance Biotherapeutics in a research report on Wednesday, October 8th. Finally, Wells Fargo & Company decreased their price target on shares of Iovance Biotherapeutics from $18.00 to $14.00 and set an “overweight” rating on the stock in a research report on Friday, August 8th. Six analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $10.80.

Iovance Biotherapeutics Price Performance

NASDAQ IOVA opened at $1.97 on Friday. Iovance Biotherapeutics has a 12 month low of $1.64 and a 12 month high of $12.51. The firm has a market capitalization of $712.84 million, a PE ratio of -1.60 and a beta of 0.83. The company’s 50 day simple moving average is $2.22 and its 200 day simple moving average is $2.32.

Hedge Funds Weigh In On Iovance Biotherapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Accredited Investors Inc. purchased a new position in Iovance Biotherapeutics during the 1st quarter worth approximately $33,000. WealthTrust Axiom LLC acquired a new stake in shares of Iovance Biotherapeutics during the 1st quarter valued at $33,000. Flputnam Investment Management Co. acquired a new stake in shares of Iovance Biotherapeutics during the 1st quarter valued at $37,000. Gould Asset Management LLC CA acquired a new stake in shares of Iovance Biotherapeutics during the 1st quarter valued at $39,000. Finally, Vontobel Holding Ltd. acquired a new stake in shares of Iovance Biotherapeutics during the 3rd quarter valued at $26,000. 77.03% of the stock is currently owned by hedge funds and other institutional investors.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.